The company said Ronald S. Lauder, a Board member, notified it on January 9, 2025 that he will retire from the Board effective January 10, 2025. He had been a Class II director since 2016, and he will remain Chairman of Clinique Laboratories LLC.

1. 01

   The company said Ronald S. Lauder, a Board member, notified it on January 9, 2025 that he will retire from the Board effective January 10, 2025. He had been a Class II director since 2016, and he will remain Chairman of Clinique Laboratories LLC.

2. 02

   Eric Zinterhofer (age 53) was elected by the Board as a Class II director, the company said. His election takes effect upon Ronald S. Lauder's retirement from the Board, and he was selected as Mr. Lauder's designee under the Stockholders' Agreement.

3. 03

   The company said the parties to the Stockholders' Agreement held Class A and Class B Common Stock with about 84% of the company's voting power as of September 30, 2024. Under the agreement, Ronald S. Lauder designated Ms. J. Lauder and Mr. Zinterhofer as directors.

4. 04

   Zinterhofer is a Founding Partner of private equity firm Searchlight Capital Partners, L.P. and a director of Charter Communications, Inc. and Liberty Latin America Ltd., the company said. It also said he is a son-in-law of Ronald S. Lauder and will receive non-employee director compensation.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.